Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms NILO-PD
- 14 Dec 2020 Results published in the JAMA Neurology
- 16 Sep 2020 Results of secondary and exploratory analysis of efficacy of nilotinib presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders